Opinion

Video

CIRCULATE-NORTH AMERICA and Barriers to Enrollment

Author(s):

John L. Marshall, MD,Benjamin Weinberg, MD

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria
Video

The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria

Apr 28th 2025 - Apr 29th 2026

online-activity
View More
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Apr 28th 2025 - Apr 29th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Related Content
mCRC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 29th 2025

Sequencing Regorafenib After Fruquintinib Improves OS in mCRC

Marwan G. Fakih, MD
March 3rd 2025

FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

Neoadjuvant Dostarlimab in dMMR Solid Tumors | Image credit: © Thipphaphone – stock.adobe.com
April 29th 2025

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

Ryan Cassaday, MD, associate professor, Clinical Research Division, Fred Hutchinson Cancer Center; associate professor, Division of Hematology and Oncology, University of Washington School of Medicine
January 23rd 2025

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

Aiwu Ruth He, MD, PhD, gastrointestinal medical oncologist, MedStar Health Lombardi Cancer Center
April 23rd 2025

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC

Colorectal Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 16th 2025

Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC